Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Using bupivacaine to reduce pain after ureteroscopy for kidney stones

Official title: Double-Blind Randomized Placebo Controlled Trial of Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain

Run by University of Chicago · NCT06635889 · Data updated 2026-11-12

This study tests if using bupivacaine in the bladder after kidney stone surgery can help reduce pain and improve comfort for patients.

More Nephrolithiasis trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment116 (estimated)
SponsorUniversity of Chicago
Academic / other
Drugs / interventionsradiation
Locations1 site (Chicago, Illinois)
StatusRecruiting
StartedMarch 26, 2025
Main results expectedOctober 2029
Study endsOctober 2029
Registry record updatedOctober 13, 2026
Trial IDNCT06635889 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older diagnosed with nephrolithiasis who are scheduled for ureteroscopy.

Probably not a fit

Patients with a history of allergy to bupivacaine or those with certain medical conditions such as chronic pain syndromes may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of instilling bupivacaine in the bladder after ureteroscopy, a procedure for treating kidney stones. It is a randomized trial comparing the effects of bupivacaine against a placebo (normal saline) on post-operative pain and urinary symptoms. The hypothesis is that bupivacaine will lead to reduced pain and improved quality of life in patients following the procedure. Participants will be monitored for their pain levels and urinary symptoms in the early post-operative period.

Why it matters

Potential benefit: If successful, this approach could significantly reduce post-operative pain and improve recovery for patients undergoing ureteroscopy.

How similar studies have gone: While the use of bupivacaine in other urologic procedures is common, this specific application following ureteroscopy has not been rigorously tested before, making it a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study.
* Male or female, aged ≥ 18 years old.
* Diagnosis of nephrolithiasis planned for flexible or semi-rigid ureteroscopy in the treatment of stone disease with ureteral stenting.

Exclusion Criteria:

* Foley catheterization
* History of allergy to bupivacaine
* Antegrade ureteroscopy
* Transplant or ectopic kidney
* Ureteral or bladder reconstruction
* Pregnancy (which is a contraindication to elective ureteroscopy)
* Dialysis
* Surgical complication (significant bleeding, ureteral perforation, significant urothelial damage)
* Suspicion of untreated urinary tract infection
* History of pelvic radiation
* Neurologic disease with a diagnosis of neurogenic bladder dysfunction
* History of chronic pain (fibromyalgia, interstitial cystitis, opioid abuse)

Where it's running

  • The University of Chicago Medical Center
    Chicago, Illinois, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.